New volunteers seeking re-infected by Ovid-19

Experts behind the study, starting this month, want to see how the immune system faces the virus for the second time.

” The ultimate goal is to draw up better treatments and vaccines. As many as 64 18-30 people will spend 17 days in a quarantine unit in a hospital suite and run numerous tests, including lung scans. They will be re-exposed to the virus, the original type from Wuhan, China, in a <x1-mededed and controlled” while the medical team monitors their health”, releases the authors of this study, reports the BBC, broadcast Albinfo.ch.

Developing Symptoms

The first phase of this study, funded by Wellcome Trust, will aim to create the lowest dose of the virus that can hold and begin repetition, but produce little or no symptoms.

This dosage will then be used to infect participants in the second phase of the study, which is expected to begin in the summer.

Volunteers who develop symptoms will be given an antibodies treatment to help them fight infection. They'll only be downloaded when they're no longer contagious.

Anti-virus therapies

The head of this study, Prof Helen McSean, from Oxford University, said:

The tests of challenges show us things that other studies cannot because, unlike natural infection, they are heavily controlled. When we re-infect these participants, we'll know exactly how their immune system has reacted to the first Covid infection, exactly when the second infection happens, and exactly how many viruses they've taken as well as improving our fundamental meaning, this can help us to draw up tests that can accurately predict if people are protected”, he said, forward of Albinfo.ch.

While Professor Lawrence Young, from Warwick University, said that human challenges studies have a long history of being able to generate important information about infections in strictly controlled conditions, and allow the efficiency of the vaccine to be accurately assessed.

“They will significantly improve our understanding of the dynamics of virus infection and immune response, as well as provide valuable information to help develop vaccines and develop anti-virus therapies, he stressed.